Epidemiology and Etiology of AML
暂无分享,去创建一个
[1] L. Möllgård,et al. The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. , 2020, Blood advances.
[2] M. Florian,et al. Understanding intrinsic hematopoietic stem cell aging , 2019, Haematologica.
[3] Ahmet Zehir,et al. Oncologic therapy shapes the fitness landscape of clonal hematopoiesis , 2019, bioRxiv.
[4] G. Juliusson,et al. Costs per Treatment Phase for AML Patients Receiving High-Dose Chemoterapy in Sweden , 2019, Blood.
[5] L. Möllgård,et al. Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period. , 2019, Blood.
[6] B. Ebert,et al. Clonal hematopoiesis in human aging and disease , 2019, Science.
[7] J. Soulier,et al. Germline DDX41 mutations define a significant entity within adult MDS/AML patients. , 2019, Blood.
[8] W. Wagner,et al. Chicken or Egg: Is Clonal Hematopoiesis Primarily Caused by Genetic or Epigenetic Aberrations? , 2019, Front. Genet..
[9] Jianwei Pan,et al. The Epidemiological Trend of Acute Myeloid Leukemia in Childhood: a Population-Based Analysis , 2019, Journal of Cancer.
[10] Xiaomei Ma,et al. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. , 2019, Blood reviews.
[11] O. Visser,et al. Incidence of acute promyelocytic leukemia across Europe: results of RARECAREnet-a population-based study. , 2019, Stem cell investigation.
[12] U. Gianelli,et al. Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options , 2019, International journal of molecular sciences.
[13] A. Shimamura,et al. Genetic predisposition to MDS: clinical features and clonal evolution. , 2019, Blood.
[14] A. Zeidan,et al. Myeloid disorders after autoimmune disease. , 2019, Best practice & research. Clinical haematology.
[15] T. Haferlach,et al. Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML , 2019, International journal of molecular sciences.
[16] Koichi Takahashi,et al. Hematologic malignancies and Li–Fraumeni syndrome , 2019, Cold Spring Harbor molecular case studies.
[17] D. Steensma. Clinical consequences of clonal hematopoiesis of indeterminate potential. , 2018, Hematology. American Society of Hematology. Education Program.
[18] Austin Carter,et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories , 2018, The Lancet.
[19] K. Ballman,et al. Somatic mutations precede acute myeloid leukemia years before diagnosis , 2018, Nature Medicine.
[20] Paolo Vineis,et al. Prediction of acute myeloid leukaemia risk in healthy individuals , 2018, Nature.
[21] L. Möllgård,et al. Acute myeloid leukemia in very old patients , 2018, Haematologica.
[22] M. Nørgaard,et al. Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national population‐based case‐control study , 2018, British journal of haematology.
[23] C. Fonatsch,et al. Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders , 2018, Blood Cancer Journal.
[24] V. Arndt,et al. Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013. , 2018, Cancer Epidemiology.
[25] L. Shlush. Age-related clonal hematopoiesis. , 2018, Blood.
[26] Juehua Gao,et al. Myeloid Neoplasm With Germline Predisposition: A 2016 Update for Pathologists. , 2018, Archives of pathology & laboratory medicine.
[27] T. Graubert,et al. Genomics in childhood acute myeloid leukemia comes of age , 2018, Nature Medicine.
[28] M. Konopleva,et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients , 2017, Cancer.
[29] A. Shimamura,et al. Genetic predisposition to hematologic malignancies: management and surveillance. , 2017, Blood.
[30] A. Dueck,et al. Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia , 2017, JAMA oncology.
[31] J. Shand. Looking up for AML in Down syndrome. , 2017, Blood.
[32] T. Fioretos,et al. Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms. , 2017, Blood.
[33] Anna L. Brown,et al. Recognition of familial myeloid neoplasia in adults. , 2017, Seminars in hematology.
[34] M. Höglund,et al. Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997–2013 , 2017, Leukemia.
[35] Lars Bullinger,et al. Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] K. Nichols,et al. Li‐Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition , 2017, British journal of haematology.
[37] Erika J. Thompson,et al. Pre-leukemic clonal hematopoiesis and the risk of therapy-related myeloid neoplasms: a case-control study , 2016, The Lancet. Oncology.
[38] B. Ebert,et al. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia , 2016, Nature Reviews Cancer.
[39] M. Höglund,et al. Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden , 2016, Leukemia.
[40] Hans Clevers,et al. Tissue-specific mutation accumulation in human adult stem cells during life , 2016, Nature.
[41] Shaoyuan Wang,et al. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis , 2016, Hematology.
[42] J. Lancet,et al. ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS , 2016, Blood Cancer Journal.
[43] E. Roman,et al. Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK’s population-based Haematological Malignancy Research Network 2004–15 , 2016, Cancer epidemiology.
[44] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[45] Shaoyuan Wang,et al. Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: a meta-analysis. , 2016 .
[46] T. Olson,et al. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults , 2016, Leukemia & lymphoma.
[47] Udit Bhaskar Bhatnagar,et al. Paclitaxel Induced MDS and AML: A Case Report and Literature Review , 2016, Case reports in oncological medicine.
[48] Anna L. Brown,et al. Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. , 2016, Blood.
[49] J. Cerhan,et al. Obesity over the life course and risk of acute myeloid leukemia and myelodysplastic syndromes. , 2016, Cancer epidemiology.
[50] A. Tefferi,et al. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors , 2015, Blood Cancer Journal.
[51] J. Gribben,et al. Disease evolution and outcomes in familial AML with germline CEBPA mutations. , 2015, Blood.
[52] B. Ebert,et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. , 2015, Blood.
[53] David B Richardson,et al. Ionising radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS): an international cohort study , 2015, The Lancet. Haematology.
[54] P. Cin,et al. Acute myeloid leukemia in a patient with constitutional 47,XXY karyotype , 2015, Leukemia research reports.
[55] L. Möllgård,et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population‐based setting: A report from the Swedish Acute Leukemia Registry , 2015, American journal of hematology.
[56] D. Neuberg,et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. , 2015, Blood.
[57] Christopher A. Miller,et al. The Role of TP53 Mutations in the Origin and Evolution of Therapy-Related AML , 2014, Nature.
[58] S. Gabriel,et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.
[59] D. Link,et al. Inherited bone marrow failure syndromes in adolescents and young adults , 2014, Annals of medicine.
[60] H. Ohnishi,et al. Age is an independent adverse prognostic factor for overall survival in acute myeloid leukemia in Japan , 2014 .
[61] M. Nørgaard,et al. Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study , 2014, Leukemia.
[62] J. Castillo,et al. The relation between cigarette smoking and risk of acute myeloid leukemia: An updated meta‐analysis of epidemiological studies , 2014, American journal of hematology.
[63] Hong Wang,et al. Comparison of Toxicity of Benzene Metabolite Hydroquinone in Hematopoietic Stem Cells Derived from Murine Embryonic Yolk Sac and Adult Bone Marrow , 2013, PloS one.
[64] A. Ogdie,et al. Characteristics and outcome of acute myeloid leukemia in patients with a prior history of autoimmune disease , 2013, Leukemia & lymphoma.
[65] R. Snyder. Leukemia and Benzene , 2012, International journal of environmental research and public health.
[66] R. Hehlmann. How I treat CML blast crisis. , 2012, Blood.
[67] A. Niemierko,et al. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] J. Mitri,et al. Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies. , 2012, Leukemia research.
[69] R. Schlenk,et al. Therapy-related myeloid neoplasms following treatment with radioiodine , 2012, Haematologica.
[70] M. Björkholm,et al. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] Frank Lyko,et al. Genome-wide promoter DNA methylation dynamics of human hematopoietic progenitor cells during differentiation and aging. , 2011, Blood.
[72] C. Klein. Genetic defects in severe congenital neutropenia: emerging insights into life and death of human neutrophil granulocytes. , 2011, Annual review of immunology.
[73] L. Kiemeney,et al. Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation , 2011, European Journal of Human Genetics.
[74] K. Döhner,et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. , 2011, Blood.
[75] T. Petrella,et al. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Côte d’Or (Burgundy, France) , 2011, Haematologica.
[76] Y. Assaraf,et al. High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. , 2010, Blood.
[77] M. Schubauer-Berigan,et al. A meta-analysis of leukaemia risk from protracted exposure to low-dose gamma radiation , 2010, Occupational and Environmental Medicine.
[78] Philip S Rosenberg,et al. Stable long‐term risk of leukaemia in patients with severe congenital neutropenia maintained on G‐CSF therapy , 2010, British journal of haematology.
[79] G. Lyman,et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] Patricia A Stewart,et al. Mortality from lymphohematopoietic malignancies and brain cancer among embalmers exposed to formaldehyde. , 2009, Journal of the National Cancer Institute.
[81] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[82] Sören Lehmann,et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. , 2009, Blood.
[83] K. Chang,et al. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] N. Shinton. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .
[85] N. Russell,et al. Advances in the understanding of susceptibility to treatment‐related acute myeloid leukaemia , 2007, British journal of haematology.
[86] Soon-Siong Teo,et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. , 2006, Blood.
[87] M. Lübbert,et al. Acute Myeloid Leukemia: Epidemiology and Etiology , 2006, Cancer.
[88] P. Galvin-Parton,et al. Severe toxicity following induction chemotherapy for acute myelogenous leukemia in a patient with Werner's syndrome , 2005, Leukemia & lymphoma.
[89] J. Reilly. Pathogenesis of acute myeloid leukaemia and inv(16)(p13;q22): a paradigm for understanding leukaemogenesis? , 2005, British journal of haematology.
[90] Shinji Yoshinaga,et al. Cancer risks among radiologists and radiologic technologists: review of epidemiologic studies. , 2004, Radiology.
[91] S. Cnattingius,et al. Maternal smoking and childhood leukemia and lymphoma risk among 1,440,542 Swedish children. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[92] M. Pettenati,et al. Hematologic malignancies and Klinefelter syndrome. a chance association? , 2002, Cancer genetics and cytogenetics.
[93] N. Harris,et al. The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.
[94] James Allan,et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[95] C Bos,et al. Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. , 2000, Blood.
[96] D. Neuberg,et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[97] J. Rowley,et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. , 1993, The New England journal of medicine.
[98] J. Pedersen‐Bjergaard,et al. Two different classes of therapy-related and de-novo acute myeloid leukemia? , 1991, Cancer genetics and cytogenetics.
[99] R. Larson,et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[100] A. Ciocco,et al. Radiation-related leukemia in Hiroshima and Nagasaki, 1946-1964. I. Distribution, incidence and appearance time. , 1966, The New England journal of medicine.
[101] R. Kostmann. Infantile Genetic Agranulocytosis (Agranulocytosis infantilis hereditaria) A New Recessive Lethal Disease in Man , 1956 .
[102] R KOSTMANN,et al. Infantile genetic agranulocytosis; agranulocytosis infantilis hereditaria. , 1956, Acta paediatrica. Supplementum.
[103] G. Klackenberg. Studies in Maternal Deprivation in Infants' Homes , 1956, Acta paediatrica.
[104] D. Lison,et al. Household exposure to pesticides and risk of leukemia in children and adolescents: Updated systematic review and meta-analysis. , 2019, International journal of hygiene and environmental health.
[105] T. Graubert,et al. Chapter 58 – Pathobiology of Acute Myeloid Leukemia , 2018 .
[106] H. McLeod,et al. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. , 2017, The Lancet. Oncology.
[107] T. Haferlach,et al. Subtype-specific patterns of molecular mutations in acute myeloid leukemia , 2017, Leukemia.
[108] Daniel J Weisdorf,et al. Acute Myeloid Leukemia. , 2015, The New England journal of medicine.
[109] A. Polednak. Recent improvement in completeness of incidence data on acute myeloid leukemia in US cancer registries. , 2014, Journal of registry management.